Compile Data Set for Download or QSAR
Report error Found 71 Enz. Inhib. hit(s) with all data for entry = 2888
TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384241(US10280184, Example F.1.4)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384242(US10280184, Example F.1.5)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384233(US10280184, Example E.1.6)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384232(US10280184, Example E.1.5)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384231(US10280184, Example E.1.4)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384230(US10280184, Example E.1.3)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384237(US10280184, Example E.1.10)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384236(US10280184, Example E.1.9)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384235(US10280184, Example E.1.8)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384234(US10280184, Example E.1.7)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384257(US10280184, Example F.1.22)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384246(US10280184, Example F.1.9)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384272(US10280184, Example F.1.38)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384269(US10280184, Example F1.35)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384276(US10280184, Example F.1.42)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384275(US10280184, Example F.1.41)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384274(US10280184, Example F.1.40)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384273(US10280184, Example F.1.39)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384261(US10280184, Example F1.26)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384224(US10280184, Example A.1.8)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384223(US10280184, Example A.1.7)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384222(US10280184, Example A.1.6)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384229(US10280184, Example E.1.2)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384228(US10280184, Example E.1.1)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384227(US10280184, Example D.1.2)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384226(US10280184, Example D.1.1)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384280(US10280184, Example G.1.4 | US10280184, Example G....)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384217(US10280184, Example A.1.1)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384279(US10280184, Example G.1.1)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384278(US10280184, Example F.1.44)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384277(US10280184, Example F.1.43)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384221(US10280184, Example A.1.5)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384220(US10280184, Example A.1.4)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384280(US10280184, Example G.1.4 | US10280184, Example G....)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384219(US10280184, Example A.1.3)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384281(US10280184, Example G.1.3)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandPNGBDBM384218(US10280184, Example A.1.2)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384239(US10280184, Example F.1.2)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384270(US10280184, Example F1.36)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384238(US10280184, Example F.1.1)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384245(US10280184, Example F.1.8)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384243(US10280184, Example F.1.6)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384264(US10280184, Example F1.30)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384263(US10280184, Example F1.29)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384262(US10280184, Example F.128)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384268(US10280184, Example F1.34)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384256(US10280184, Example F.1.21)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384255(US10280184, Example F.1.20)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384254(US10280184, Example F.1.19)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandPNGBDBM384286(US10280184, Example I.1.4)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

Displayed 1 to 50 (of 71 total ) | Next | Last >>
Jump to: